Lykos Therapeutics Strategic Reorganization Following FDA's Decision Rejecting MDMA For PTSD Treatment
Lykos Therapeutics announces a strategic reorganization to address the FDA's decision on midomafetamine capsules for PTSD, appointing Dr. David Hough as senior medical advisor and reducing its workforce by 75%.
